secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001835268-25-000057
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma Q3 net loss $17.2M; cash $54.8M; Seabreeze STAT studies on track for 1H26 topline
--------------------------------------------------------------------------------

- Net loss of $17.2M ($0.31 per share) in Q3 2025 vs $12.9M ($0.23) in Q3 2024; 9-month net loss $40.4M ($0.73) vs $6.7M ($0.12).
- License revenue dropped to $16K (Q3) and $64K (9M) from $1.2M and $25.3M in prior-year periods due to upfront and milestone recognition in 2024.
- R&D expense increased to $11.1M (Q3) from $9.0M, reflecting initiation of Phase 2 Seabreeze STAT asthma/COPD studies.
- Simcere NDA for rademikibart in atopic dermatitis accepted by China NMPA; Connect eligible for up to ~$110M in milestones plus tiered royalties.
- Phase 2 Seabreeze STAT studies recruiting participants; topline data expected 1H2026. Cash position of $54.8M expected to fund operations into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000057/0001835268-25-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526825000057/cntb-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001835268-25-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer